Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

British New Lung Cancer Drug Wins Approval in China

Page View:

        The London stock market listed that the China Food and Drug Administration (CFDA) have granted marketing authorization for its lung cancer pill Tagrisso in China.   

Medicilon boasts nearly 300 tumor evaluation models. At the same time, we are empowering innovative therapies to comprehensively evaluate and study immuno-oncology. We have completed model establishment and efficacy evaluation of immuno-therapies such as CAR-T, TCR-T, CAR-NK, oncolytic virus, antibody (monoclonal antibody, double antibody, polyclonal antibody, etc.), siRNA, AAV.



        Tagrisso (osimertinib) is designed for the treatment of adult patients with certain genetic mutations, which is the first AstraZeneca medicine approved under the CFDA’s Priority Review pathway, using an accelerated timeline for an innovative medicine.


        Sean Bohlen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “This is an important step forward for Tagrisso and a significant opportunity to bring a breakthrough medicine to patients with NSCLC (non-small cell lung cancer) in China, where EGFR (epidermal growth factor receptor) rates are some of the highest in the world.”


Related Articles:

Immunotherapy Combo for Metastatic Lung Cancer Shows Success

Novel Lung Cancer Biomarkers Identified

Discovery Could Guide Immunotherapy for Lung Cancer

    According to the company, the rapid review and approval signal the urgent need for new, targeted treatments with the potential to address specific types of cancer with high incidence rate and significant unmet medical need in China.

Relevant newsRelevant news